Pere Mañé Takes the Helm as CEO at Suanfarma
Suanfarma, an innovative global company that excels in the development, production, and commercialization of active pharmaceutical ingredients (APIs) and high-value Contract Development and Manufacturing Organization (CDMO) services for the health industry, is thrilled to announce the appointment of Pere Mañé Godina as its new Chief Executive Officer (CEO). This significant leadership change heralds an exciting chapter aimed at enhancing industrial consolidation, fostering sustainable innovation, and driving global expansion.
Pere Mañé's Extensive Experience in the Pharmaceutical Sector
Pere brings over 30 years of rich experience in the pharmaceutical realm, having occupied various technical and strategic executive roles within prestigious companies like Uquifa, Boehringer Ingelheim, and Esteve Química (part of the Esteve Group). His career reflects a diverse range of expertise encompassing technical oversight, operational management, and high-level executive positions including General Manager and Group Chief Industrial Operations Officer.
Achievements That Stand Out
In his most recent role at Esteve, Pere was influential in driving the company through significant industrial transformation, effectively positioning its chemical division as a global benchmark within the industry. Under his guidance, Esteve was honored as the CDMO of the Year in the Small Molecules category at the esteemed DCAT Leadership Awards. This accolade underscores his commitment to excellence and innovation in pharmaceutical development.
A Vision Aligned with Strategic Growth
The appointment of Pere Mañé is closely aligned with Suanfarma's long-term vision and aspirations. Carlos Alonso, who has been serving as the interim CEO since October, will aid in ensuring a seamless transition while continuing to contribute to the company's success as Executive Chairman. Pere’s leadership approach promises to infuse fresh energy and direction into the company.
In reflecting on this transition, Carlos stated, "We are confident that Pere's deep sector knowledge, strategic mindset, and leadership experience will be instrumental in strengthening Suanfarma's market position and continuing to deliver high-value solutions to our customers and partners." This shared vision lays a robust foundation for the next phase of growth for Suanfarma.
Focusing on Key Objectives
Pere’s appointment signifies a renewed momentum towards Suanfarma's growth journey, emphasizing crucial areas such as:
- Streamlining industrial operations and integrating cutting-edge technologies
- Strengthening collaborations with global clients and essential suppliers
- Accelerating international market expansion
- Promoting a culture of innovation and sustainability across all operations
Pere Mañé's Vision for Suanfarma
As Pere Mañé Godina articulates, "Suanfarma has all the elements to lead the future of the industry: a solid foundation, a strong industrial platform, and a high-value international network supported by an exceptional team. I'm excited to begin this new chapter and work together to keep delivering innovative, efficient, and sustainable solutions to our clients." His enthusiasm is infectious as he gears up to steer the company towards a promising future.
About Suanfarma
Established in 1993, Suanfarma has carved a niche as a B2B partner in the life sciences sector, dedicated to health and innovation through the sustainable development and distribution of high-quality pharmaceutical ingredients. With a strong presence in over 70 countries, Suanfarma has been part of the healthcare-focused investment firm Archimed since 2021, further amplifying its joint mission towards excellence in the healthcare landscape.
Frequently Asked Questions
Who is the new CEO of Suanfarma?
Pere Mañé Godina has been appointed as the new CEO of Suanfarma.
What experience does Pere Mañé have?
Pere has over 30 years of experience in the pharmaceutical sector, holding various executive positions in leading companies.
What are the key objectives for Suanfarma under Pere's leadership?
Key objectives include streamlining operations, strengthening client relationships, and promoting innovation.
What past achievements highlight Pere Mañé's capabilities?
He played a crucial role in Esteve's industrial transformation and was recognized as the CDMO of the Year for Small Molecules.
What does Suanfarma do?
Suanfarma specializes in developing and manufacturing active pharmaceutical ingredients and offers CDMO services globally.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.